Evotec and DiscoveRx form screening services partnership
Evotec and DiscoveRx Corporation of Fremont, California, US signed co-marketing agreement
Evotec and DiscoveRx Corporation of Fremont, California, US, a provider of cell based assay solutions, have signed a co-marketing agreement for the screening of GPCR's and other targets.
Under the terms of the agreement, Evotec will have access to DiscoveRx's PathHunter and cAMPHunter cell lines and proprietary EFC chemiluminescent detection technology for use during hit identification and optimisation projects performed for Evotec customers, using the company's proprietary high throughput screening technology.
DiscoveRx's EFC related technologies offer assay solutions for every major class of drug target, including GPCRs, kinases, proteases, nuclear hormone receptors, and secreted proteins. In addition, EFC-based PathHunter and HitHunter cAMP assays are said to be market leaders in GPCR screening applications. Evotec says it can now offer unrivalled screening solutions within the drug discovery process for GPCRs and other targets.
"This agreement means that DiscoveRx's innovative assay portfolio of more than 300 cell based GPCR assays can be accessed in conjunction with the first-class high throughput screening set-up at Evotec. This will provide significant value to our screening partners, specifically in the area of GPCR screening," said Dr Mark Ashton, Evotec's executive vice president, business development.
